Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,162 across all filing types
Latest filing 2017-04-21 Major Shareholding Noti…
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2017
Major Shareholding Notification
2017-04-21 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 20, 2017, reporting the completion of an acquisition transaction by PTC Therapeutics, Inc. It details the acquisition of rights to Emflaza, including the terms of the asset purchase agreement, stock issuance, contingent payments, and related agreements. The document includes legal and financial transaction details but does not contain comprehensive financial statements or quarterly/yearly financial results. It is a current report disclosing a material event (completion of acquisition) rather than a full financial report or earnings release. Therefore, it fits the category of a Regulatory Filing (RNS), which is a general category for miscellaneous SEC filings that do not fit other specific categories like Annual Report, Earnings Release, or M&A filings that are more formal merger proxy statements or tender offers. The document is detailed and substantive, so confidence is high.
2017-04-20 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated April 11, 2017, for PTC Therapeutics, Inc. The key content is under Item 5.02, which reports the departure of a board member, Mr. Ronald Renaud, who will not stand for re-election at the upcoming annual meeting. This is a clear announcement of a change in the company's board of directors. The document does not contain financial data, audit information, or other report types. It is specifically about board/management changes, fitting the category of Board/Management Information (MANG). The document length is 2717 characters, which is typical for an 8-K reporting management changes. Therefore, the classification is MANG with high confidence.
2017-04-17 English
Regulatory Filings 2017
Regulatory Filings
2017-04-11 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes the resignation of a key executive (CFO), and an update on the early termination of the Hart-Scott-Rodino waiting period for an acquisition transaction. These are announcements about management changes and transaction progress, not detailed financial reports or earnings releases. The document also references an attached press release. The primary focus is on the departure of a director/officer and corporate development updates. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). Therefore, the correct classification is MANG with high confidence.
2017-04-10 English
SEC SCHEDULE 13G
Major Shareholding Notification
2017-04-10 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.